Tocilizumab in COVID-19 therapy: who benefits, and how?
作者信息
Neumann Avidan U, Goekkaya Mehmet, Dorgham Karim, Traidl-Hoffmann Claudia, Gorochov Guy
机构信息
Department of Environmental Medicine, Faculty of Medicine, Universitätsklinikum Augsburg, Augsburg, Germany; Institute of Environmental Medicine, Helmholtz Center Munich, Augsburg, Germany.
Department of Environmental Medicine, Faculty of Medicine, Universitätsklinikum Augsburg, Augsburg, Germany; Environmental Medicine, Technical University Munich, Munich, Germany.
出版信息
Lancet. 2021 Jul 24;398(10297):299-300. doi: 10.1016/S0140-6736(21)01427-6.
Abstract
摘要
相似文献
1
Tocilizumab in COVID-19 therapy: who benefits, and how?
Lancet. 2021 Jul 24;398(10297):299-300. doi: 10.1016/S0140-6736(21)01427-6.
2
Tocilizumab in COVID-19 therapy: who benefits, and how?
Lancet. 2021 Jul 24;398(10297):299. doi: 10.1016/S0140-6736(21)01380-5.
3
Tocilizumab in COVID-19 therapy: who benefits, and how? - Authors' reply.
Lancet. 2021 Jul 24;398(10297):300. doi: 10.1016/S0140-6736(21)01422-7.
4
Benign SARS-CoV-2 infection in MOG-antibodies associated disorder during tocilizumab treatment.
Mult Scler Relat Disord. 2020 Nov;46:102592. doi: 10.1016/j.msard.2020.102592. Epub 2020 Oct 21.
5
Tocilizumab: From Rheumatic Diseases to COVID-19.
Curr Pharm Des. 2021;27(13):1597-1607. doi: 10.2174/1381612827666210311141512.
6
Tocilizumab administration in patients with SARS-CoV-2 infection: Subcutaneous injection vs intravenous infusion.
J Med Virol. 2021 Jan;93(1):69-70. doi: 10.1002/jmv.26124. Epub 2020 Jun 19.
7
Tocilizumab therapy and COVID-19.
J Osteopath Med. 2021 Aug 13;121(11):865. doi: 10.1515/jom-2021-0181.
8
The effect of tocilizumab, anakinra and prednisolone on antibody response to SARS-CoV-2 in patients with COVID-19: A prospective cohort study with multivariate analysis of factors affecting the antibody response.
Int J Infect Dis. 2021 Apr;105:756-762. doi: 10.1016/j.ijid.2021.03.031. Epub 2021 Mar 15.
9
Impact of Timing of Tocilizumab Use in Hospitalized Patients With SARS-CoV-2 Infection.
Respir Care. 2022 May;67(5):629-630. doi: 10.4187/respcare.10067.
10
Response to "Tocilizumab therapy and COVID-19".
J Osteopath Med. 2021 Sep 8;121(11):867-868. doi: 10.1515/jom-2021-0212.
引用本文的文献
1
COVID-19: A state of art on immunological responses, mutations, and treatment modalities in riposte.
J Infect Public Health. 2023 Feb;16(2):233-249. doi: 10.1016/j.jiph.2022.12.019. Epub 2022 Dec 29.
2
Biomarkers during COVID-19: Mechanisms of Change and Implications for Patient Outcomes.
Diagnostics (Basel). 2022 Feb 16;12(2):509. doi: 10.3390/diagnostics12020509.
3
Immune Profiling of COVID-19 in Correlation with SARS and MERS.
Viruses. 2022 Jan 17;14(1):164. doi: 10.3390/v14010164.
4
SARS-CoV-2 neutralizing antibodies decline over one year and patients with severe COVID-19 pneumonia display a unique cytokine profile.
Int J Infect Dis. 2021 Nov;112:227-234. doi: 10.1016/j.ijid.2021.09.021. Epub 2021 Sep 15.
本文引用的文献
1
Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.
Lancet. 2021 May 1;397(10285):1637-1645. doi: 10.1016/S0140-6736(21)00676-0.
2
Distinct cytokine profiles associated with COVID-19 severity and mortality.
J Allergy Clin Immunol. 2021 Jun;147(6):2098-2107. doi: 10.1016/j.jaci.2021.03.047. Epub 2021 Apr 22.
3
Sarilumab in patients admitted to hospital with severe or critical COVID-19: a randomised, double-blind, placebo-controlled, phase 3 trial.
Lancet Respir Med. 2021 May;9(5):522-532. doi: 10.1016/S2213-2600(21)00099-0. Epub 2021 Mar 4.
4
IL-6 serum levels predict severity and response to tocilizumab in COVID-19: An observational study.
J Allergy Clin Immunol. 2021 Jan;147(1):72-80.e8. doi: 10.1016/j.jaci.2020.09.018. Epub 2020 Sep 30.
5
An inflammatory cytokine signature predicts COVID-19 severity and survival.
Nat Med. 2020 Oct;26(10):1636-1643. doi: 10.1038/s41591-020-1051-9. Epub 2020 Aug 24.
Zotero 插件